<DOC>
	<DOCNO>NCT00535847</DOCNO>
	<brief_summary>To provide access telaprevir-based treatment subject Control Group Study VX06-950-106 ( NCT00420784 ) , VX05-950-104 ( NCT00336479 ) , VX05-950-104EU ( NCT00372385 ) stop treatment due inadequate response treatment . Safety , tolerability , Hepatitis C Virus ( HCV ) Ribonucleic Acid ( RNA ) level collect .</brief_summary>
	<brief_title>A Rollover Study Subjects Participating Control Arm Study VX06-950-106 , VX05-950-104 VX05-950-104EU Whose Plasma Hepatitis C Virus ( HCV ) Ribonucleic Acid ( RNA ) Levels Did Not Respond Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Enrolled control arm Study VX06950106 ( NCT00420784 ) , VX05950104 ( NCT00336479 ) VX05950104EU ( NCT00372385 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Genotype 1</keyword>
</DOC>